A comparison of complementary measures of vitamin B6 status, function, and metabolism in the European Prospective Investigation into Cancer and Nutrition (EPIC) study.


Journal

The American journal of clinical nutrition
ISSN: 1938-3207
Titre abrégé: Am J Clin Nutr
Pays: United States
ID NLM: 0376027

Informations de publication

Date de publication:
01 07 2021
Historique:
received: 23 10 2020
accepted: 08 02 2021
pubmed: 9 4 2021
medline: 8 9 2021
entrez: 8 4 2021
Statut: ppublish

Résumé

Vitamin B6 insufficiency has been linked to increased risk of cancer and other chronic diseases. The circulating concentration of pyridoxal 5'-phosphate (PLP) is a commonly used measure of vitamin B6 status. Ratios of substrates indicating PLP coenzymatic function and metabolism may be useful complementary measures to further explore the role of vitamin B6 in health. We explored the sensitivity of 5 outcomes, namely PLP concentration, homocysteine:cysteine (Hcy:Cys), cystathionine:cysteine (Cysta:Cys), the 3´-hydroxykynurenine ratio (HKr), and the 4-pyridoxic acid ratio (PAr) to vitamin B6 intake as well as personal and lifestyle characteristics. Dietary intake and biomarker data were collected from participants from 3 nested case-control studies within the European Prospective Investigation into Cancer and Nutrition (EPIC). Bayesian regression models assessed the associations of the 5 biomarker outcomes with vitamin B6 intake and personal and lifestyle covariates. Analogous models examined the relations of Hcy:Cys, Cysta:Cys, and HKr with PLP. In total, 4608 participants were included in the analyses. Vitamin B6 intake was most strongly associated with PLP, moderately associated with Hcy:Cys, Cysta:Cys, and HKr, and not associated with PAr (fold change in marker given a doubling of vitamin B6 intake: PLP 1.60 [95% credible interval (CrI): 1.50, 1.71]; Hcy:Cys 0.87 [95% CrI: 0.84, 0.90]; Cysta:Cys 0.89 [95% CrI: 0.84, 0.94]; HKr 0.88 [95% CrI: 0.85, 0.91]; PAr 1.00 [95% CrI: 0.95, 1.05]). PAr was most sensitive to age, and HKr was least sensitive to BMI and alcohol intake. Sex and menopause status were strongly associated with all 5 markers. We found that 5 different markers, capturing different aspects of vitamin B6-related biological processes, varied in their associations with vitamin B6 intake and personal and lifestyle predictors.

Sections du résumé

BACKGROUND
Vitamin B6 insufficiency has been linked to increased risk of cancer and other chronic diseases. The circulating concentration of pyridoxal 5'-phosphate (PLP) is a commonly used measure of vitamin B6 status. Ratios of substrates indicating PLP coenzymatic function and metabolism may be useful complementary measures to further explore the role of vitamin B6 in health.
OBJECTIVES
We explored the sensitivity of 5 outcomes, namely PLP concentration, homocysteine:cysteine (Hcy:Cys), cystathionine:cysteine (Cysta:Cys), the 3´-hydroxykynurenine ratio (HKr), and the 4-pyridoxic acid ratio (PAr) to vitamin B6 intake as well as personal and lifestyle characteristics.
MEDTHODS
Dietary intake and biomarker data were collected from participants from 3 nested case-control studies within the European Prospective Investigation into Cancer and Nutrition (EPIC). Bayesian regression models assessed the associations of the 5 biomarker outcomes with vitamin B6 intake and personal and lifestyle covariates. Analogous models examined the relations of Hcy:Cys, Cysta:Cys, and HKr with PLP.
RESULTS
In total, 4608 participants were included in the analyses. Vitamin B6 intake was most strongly associated with PLP, moderately associated with Hcy:Cys, Cysta:Cys, and HKr, and not associated with PAr (fold change in marker given a doubling of vitamin B6 intake: PLP 1.60 [95% credible interval (CrI): 1.50, 1.71]; Hcy:Cys 0.87 [95% CrI: 0.84, 0.90]; Cysta:Cys 0.89 [95% CrI: 0.84, 0.94]; HKr 0.88 [95% CrI: 0.85, 0.91]; PAr 1.00 [95% CrI: 0.95, 1.05]). PAr was most sensitive to age, and HKr was least sensitive to BMI and alcohol intake. Sex and menopause status were strongly associated with all 5 markers.
CONCLUSIONS
We found that 5 different markers, capturing different aspects of vitamin B6-related biological processes, varied in their associations with vitamin B6 intake and personal and lifestyle predictors.

Identifiants

pubmed: 33829249
pii: S0002-9165(22)00334-3
doi: 10.1093/ajcn/nqab045
pmc: PMC8246608
doi:

Substances chimiques

Vitamin B 6 8059-24-3

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

338-347

Subventions

Organisme : Cancer Research UK
ID : 24390
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 25004
Pays : United Kingdom
Organisme : Medical Research Council
ID : 1000143
Pays : United Kingdom

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of the American Society for Nutrition.

Références

Eur J Clin Nutr. 2009 Nov;63 Suppl 4:S122-49
pubmed: 19888270
J Nutr. 2013 Jun;143(6):957S-65S
pubmed: 23576641
J Natl Cancer Inst. 2014 Nov 05;106(12):
pubmed: 25376861
Am J Clin Nutr. 2020 Jan 1;111(1):178-186
pubmed: 31557280
Anal Chem. 2016 Nov 1;88(21):10427-10436
pubmed: 27715010
Eur J Clin Nutr. 2009 Nov;63 Suppl 4:S226-38
pubmed: 19888276
Int J Epidemiol. 1997;26 Suppl 1:S6-14
pubmed: 9126529
Nutrients. 2017 Jan 10;9(1):
pubmed: 28075382
Int J Cancer. 2015 Feb 15;136(4):915-27
pubmed: 24975698
BMC Syst Biol. 2018 Oct 24;12(1):89
pubmed: 30355281
J Am Diet Assoc. 2010 Nov;110(11):1660-8
pubmed: 21034879
Br J Nutr. 2013 Jul 28;110(2):363-74
pubmed: 23228223
Rapid Commun Mass Spectrom. 2009 May;23(9):1371-9
pubmed: 19337982
Am J Clin Nutr. 2008 May;87(5):1446-54
pubmed: 18469270
Eur J Clin Nutr. 2010 Aug;64(8):905-13
pubmed: 20502473
J Gerontol A Biol Sci Med Sci. 2020 Jan 20;75(2):374-379
pubmed: 30657862
J Clin Pathol. 1991 Jul;44(7):592-5
pubmed: 1856292
J Gerontol A Biol Sci Med Sci. 1996 Nov;51(6):B417-24
pubmed: 8914491
Annu Rev Nutr. 1999;19:217-46
pubmed: 10448523
Int J Epidemiol. 1997;26 Suppl 1:S1-5
pubmed: 9126528
JAMA. 2010 Jun 16;303(23):2377-85
pubmed: 20551408
J Nutr. 2009 Apr;139(4):784-91
pubmed: 19244383
Nutrients. 2016 Sep 01;8(9):
pubmed: 27598193
Annu Rev Nutr. 2015;35:33-70
pubmed: 25974692
Methods Enzymol. 1997;281:43-53
pubmed: 9250965
Sci Rep. 2017 Dec 14;7(1):17559
pubmed: 29242525
Am J Clin Nutr. 2014 Jul;100(1):250-5
pubmed: 24808485
Eur J Clin Nutr. 2007 Sep;61(9):1037-56
pubmed: 17375121
PLoS One. 2018 May 7;13(5):e0196465
pubmed: 29734388
Crit Rev Food Sci Nutr. 2019;59(16):2697-2707
pubmed: 30431328
Annu Rev Public Health. 2016;37:17-32
pubmed: 26653405
J Nutr. 2017 Jun;147(6):1167-1173
pubmed: 28381531
J Exp Bot. 2005 Jan;56(410):267-72
pubmed: 15545297
Public Health Nutr. 2002 Dec;5(6B):1113-24
pubmed: 12639222
Clin Chem. 2005 Nov;51(11):2103-9
pubmed: 16123148
Am J Clin Nutr. 2018 Sep 1;108(3):611-621
pubmed: 30101351
Clin Chem. 2010 May;56(5):755-63
pubmed: 20299681
J Hepatol. 2010 Sep;53(3):551-7
pubmed: 20561703
Int J Cancer. 2019 Mar 1;144(5):947-956
pubmed: 29786139
Cancer Res. 2018 Jan 1;78(1):302-308
pubmed: 29070616
J Natl Cancer Inst. 2017 Mar 1;109(3):1-9
pubmed: 28376200
Int J Cancer. 2015 Jun 15;136(12):2932-9
pubmed: 25404109

Auteurs

Joanna L Clasen (JL)

Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom.

Alicia K Heath (AK)

Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom.

Heleen Van Puyvelde (H)

International Agency for Research on Cancer, Lyon, France.
Department of Public Health and Primary Care, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.

Inge Huybrechts (I)

International Agency for Research on Cancer, Lyon, France.

Jin Young Park (JY)

International Agency for Research on Cancer, Lyon, France.

Pietro Ferrari (P)

International Agency for Research on Cancer, Lyon, France.

Mattias Johansson (M)

International Agency for Research on Cancer, Lyon, France.

Ghislaine Scelo (G)

Cancer Epidemiology Unit, University of Turin, Turin, Italy.

Arve Ulvik (A)

Department of Clinical Science, University of Bergen, Bergen, Hordaland, Norway.

Øivind Midttun (Ø)

Bevital A/S, Bergen, Norway.

Per Magne Ueland (PM)

Department of Clinical Science, University of Bergen, Bergen, Hordaland, Norway.

Christina C Dahm (CC)

Department of Public Health, Aarhus University, Aarhus, Denmark.

Jytte Halkjær (J)

Danish Cancer Society Research Center, Diet, Genes and Environment, Copenhagen, Denmark.

Anja Olsen (A)

Danish Cancer Society Research Center, Diet, Genes and Environment, Copenhagen, Denmark.

Theron Johnson (T)

German Cancer research Center (DKFZ), Heidelberg, Germany.

Verena Katzke (V)

German Cancer research Center (DKFZ), Heidelberg, Germany.

Matthias B Schulze (MB)

Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.
Institute of Nutritional Science, University of Potsdam, Nuthetal, Germany.

Giovanna Masala (G)

Cancer Risk Factors and Life-Style Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network - ISPRO, Florence, Italy.

Francesco Segrado (F)

Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.

Maria Santucci de Magistris (MS)

AOU Federico II, Naples, Italy.

Carlotta Sacerdote (C)

Unit of Cancer Epidemiology, Città della Salute e della Scienza University-Hospital, Turin Italy.

Marga C Ocké (MC)

National Institute for Public Health and the Environment, Bilthoven, The Netherlands.

Leila Luján-Barroso (L)

Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Barcelona, Spain.
Bellvitge Biomedical Research Institute - IDIBELL, L'Hospitalet de 18 Llobregat, Barcelona, Spain.

Ana Ching-López (A)

Escuela Andaluza de Salud Pública (EASP), Granada, Spain.
Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.

José María Huerta (JM)

Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain.
CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.

Eva Ardanaz (E)

CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Navarra Public Health Institute, Pamplona, Spain.
IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.

Pilar Amiano (P)

Public Health Division of Gipuzkoa, BioDonostia Research Institute, San Sebastian; CIBER Epidemiología y Salud Pública, Madrid, Spain.

Ulrika Ericson (U)

Department of Clinical Sciences in Malmö, Lund University, Malmö, Sweden.

Jonas Manjer (J)

Dept of Surgery, Skåne University Hospital Malmö, Lund University, Malmö, Sweden.

Björn Gylling (B)

Department of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden.

Ingegerd Johansson (I)

Department of Odontology, Umeå University, Umeå, Sweden.

Julie Schmidt (J)

Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.

Elisabete Weiderpass (E)

International Agency for Research on Cancer, Lyon, France.

Elio Riboli (E)

Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom.

Amanda J Cross (AJ)

Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom.

David C Muller (DC)

Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom.
Department of Epidemiology and Biostatistics, School of Public Health, MRC-PHE Centre for Environment and Health, Imperial College London, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH